Icatibant Universal Farma

Icatibant, the active ingredient in Icatibant Universal Farma, is a bradykinin B2 receptor antagonist presented as an injection solution for subcutaneous use. It treats acute attacks of hereditary angioedema in adults, including type I and type II forms of the disease.

GNH USA supplies Icatibant Universal Farma as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide.

Icatibant is a targeted therapy for hereditary angioedema, acting on the bradykinin pathway to relieve swelling.

- Acute hereditary angioedema attacks: rapid reduction of swelling and pain in adults. - Hereditary angioedema type I: alleviates attack‑related edema when administered promptly. - Hereditary angioedema type II: provides fast symptom control during acute episodes.

Icatibant may cause a range of adverse reactions, most of which are mild and transient.

Common Side Effects: - Injection site pain: discomfort at the site of subcutaneous injection. - Redness or erythema: localized skin irritation. - Swelling at injection site: mild edema around the needle entry. - Nausea: occasional gastrointestinal upset. - Headache: mild to moderate head discomfort. - Dizziness: transient light‑headedness.

Serious or Rare Side Effects: - Hypersensitivity reactions: rash, itching, or hives. - Anaphylaxis: severe allergic response requiring immediate medical attention. - Severe hypotension: marked drop in blood pressure. - Worsening angioedema: paradoxical increase in swelling. - Infection at injection site: signs of local infection. - Thrombocytopenia: low platelet count observed in rare cases.

Before using Icatibant, consider the following safety measures.

- Pregnancy: safety not established; use only if benefit outweighs potential risk. - Breastfeeding: unknown effects; weigh risks and benefits before administration. - Renal impairment: exercise caution and monitor renal function. - Concomitant ACE inhibitors: monitor for increased bradykinin‑related angioedema. - Known hypersensitivity: discontinue immediately if allergic reaction occurs. - Store at 2-8°C: keep refrigerated, protect from light, do not freeze or shake.

Icatibant can interact with other medicines that influence bradykinin levels or blood pressure.

Major Interactions (Avoid): - ACE inhibitors: may increase bradykinin, raising risk of angioedema. - Angiotensin receptor blockers: similar potential to elevate bradykinin. - Other bradykinin B2 antagonists: additive pharmacologic effect.

Moderate Interactions (Monitor Closely): - Diuretics: monitor blood pressure and electrolyte balance. - NSAIDs: may exacerbate edema or affect renal function. - Estrogen‑containing contraceptives: possible influence on HAE severity. - Antihistamines: may mask early signs of hypersensitivity. - Corticosteroids: monitor for overlapping immunomodulatory effects.